Much work remains to optimize further anti-inflammatory interventions, minimize unwanted actions, and refine patient selection. This long road from discovery in the laboratory to successful clinical trials represents a victory for medical science, and opens a new avenue to reducing the risk that remains despite current treatments for atherosclerosis.
No takes yet. Share an insight, caveat, or question.
Peter Libby (2020) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: